News

EHP-101 Phase 2a Trial Cleared to Move to High Dose Groups

A Phase 2a clinical trial testing the oral cannabidiol-derived medication EHP-101 in people with diffuse cutaneous systemic sclerosis can proceed to the higher dose groups, the therapy candidate’s developer Emerald Health Pharmaceuticals (EHP) announced. The study is taking place in the U.S., including Puerto Rico, as well as…

ADAR1 May Be Therapeutic Target for SSc: Mouse Study

The protein ADAR1 occurs in great amounts in macrophages, a type of immune cell that appears in the early stages of systemic sclerosis (SSc), making the cells more active and stirring up a “turmoil” of inflammation, a mouse study found. Researchers also observed that mice in which the disease…

Centromere Defects Linked to SSc Autoimmunity

A new study has found that defects in centromeres — specific regions of chromosomes — are evident in skin cells from people with systemic sclerosis (SSc). People with diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) forms of the disease showed specific alterations relative to healthy people, but chromosomal…